Abstract
We investigated the association ofFcgammaRIIIaa and FcgRIIa polymorphisms and response to R-CHOP in 58 patients with diffuse large B-cell lymphoma (DLBCL). FcgammaRIIIa and FcgRIIa polymorphisms did not influence response, event-free or overall survival. These results suggest that ADCC via FcgammaRIIIa and FcgammaRIIa may not be the major mechanism of activity of the R-CHOP combination in DLBCL.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD / genetics*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / therapeutic use
-
Female
-
Humans
-
Lymphoma, B-Cell / diagnosis
-
Lymphoma, B-Cell / drug therapy
-
Lymphoma, B-Cell / genetics
-
Lymphoma, Large B-Cell, Diffuse / diagnosis*
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Lymphoma, Large B-Cell, Diffuse / genetics
-
Male
-
Middle Aged
-
Polymorphism, Genetic*
-
Prednisone / therapeutic use
-
Receptors, IgG / genetics*
-
Rituximab
-
Survival Analysis
-
Treatment Outcome
-
Vincristine / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD
-
FCGR3A protein, human
-
Fc gamma receptor IIA
-
Receptors, IgG
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone